成人心脏骤停后的温度控制:更新的系统评价与荟萃分析
本系统评价与荟萃分析为2021年发表的系统评价的更新,检索截至2023年5月31日,纳入成人心脏骤停的对照试验,评估温度控制各方面。针对32-34°C vs 正常体温或36°C,共7项试验纳入更新荟萃分析,32-34°C未改善90-180天生存(RR 1.06,95%CI 0.91-1.23)或良好神经功能预后(RR 1.27,95%CI 0.89-1.81),证据确定性低。按院内 vs 院外亚组分析结果相似;9项试验的敏感性分析(任何时间点良好神经功能预后)亦未显示改善(RR 1.14,95%CI 0.98-1.34)。新试验比较31-34°C、12-24小时 vs 36小时温度控制、0.25-0.5°C/小时复温速率及发热预防,均未发现差异。
要点
- 32-34°C目标温度控制 vs 正常体温或36°C:90-180天生存RR 1.06(95%CI 0.91-1.23),良好神经功能预后RR 1.27(95%CI 0.89-1.81),证据确定性低。
- 按院内心脏骤停 vs 院外心脏骤停亚组分析,32-34°C vs 正常体温或36°C结果相似。
- 9项试验敏感性分析:32-34°C vs 正常体温或36°C,任何时间点良好神经功能预后RR 1.14(95%CI 0.98-1.34),未显示改善。
- 新试验比较31-34°C目标、12-24小时 vs 36小时温度控制、0.25-0.5°C/小时复温速率及发热预防,均未发现结局差异。
- 95%CI不能排除32-34°C的潜在获益;低温目标、复温速率和发热控制仍存在重要知识空白。
适用人群与场景
- 成人心脏骤停患者,纳入对照试验。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析(2021年系统评价的更新),检索PubMed、Embase和Cochrane Central Register of Controlled Trials,截至2023年5月31日,纳入人类对照试验,采用随机效应模型合并数据,GRADE评估证据确定性。
- 更新检索识别6项新试验;多数结局的偏倚风险评为中等。
- 32-34°C vs 正常体温或36°C:2项新试验,共7项试验纳入更新荟萃分析;心脏骤停后90-180天生存RR 1.06(95%CI 0.91-1.23),良好神经功能预后RR 1.27(95%CI 0.89-1.81),证据确定性低。
- 按心脏骤停地点(院内 vs 院外)亚组分析结果相似。
- 敏感性分析(9项试验)比较32-34°C vs 正常体温或36°C对任何时间点良好神经功能预后的影响,RR 1.14(95%CI 0.98-1.34),未显示改善。
- 新个体试验比较31-34°C目标、12-24小时 vs 36小时温度控制、0.25-0.5°C/小时复温速率及发热预防效果,均未发现结局差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入对照试验,采用GRADE评估证据确定性。
- 32-34°C vs 正常体温或36°C的生存和良好神经功能预后结局为低确定性证据。
- 多数结局的偏倚风险评为中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 更新系统评价显示32-34°C目标温度控制相较于正常体温或36°C无获益,但95%CI不能排除潜在获益。
- 低温温度目标、复温速率和发热控制等主题存在重要知识空白。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To perform an updated systematic review and meta-analysis on temperature control in adult patients with cardiac arrest.
METHODS: The review is an update of a previous systematic review published in 2021. An updated search including PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed on May 31, 2023. Controlled trials in humans were included. The population included adult patients with cardiac arrest. The review included all aspects of temperature control including timing, temperature, duration, method of induction and maintenance, and rewarming. Two investigators reviewed trials for relevance, extracted data, and assessed risk of bias. Data were pooled using random-effects models. Certainty of evidence was evaluated using GRADE.
RESULTS: The updated systematic search identified six new trials. Risk of bias in the trials was assessed as intermediate for most of the outcomes. For temperature control with a target of 32-34 °C vs. normothermia or 36 °C, two new trials were identified, with seven trials included in an updated meta-analysis. Temperature control with a target of 32-34 °C did not result in an improvement in survival (risk ratio: 1.06 [95%CI: 0.91, 1.23]) or favorable neurological outcome (risk ratio: 1.27 [95%CI: 0.89, 1.81]) at 90-180 days after the cardiac arrest (low certainty evidence). Subgroup analysis according to location of cardiac arrest (in-hospital vs. out-of-hospital) found similar results. A sensitivity analysis of nine trials comparing temperature control at 32-34 °C to normothermia or 36 °C for favorable neurological outcome at any time point also did not show an improvement in outcomes (risk ratio: 1.14 [95%CI 0.98, 1.34]). New individual trials comparing a target of 31-34 °C, temperature control for 12-24 hours to 36 hours, a rewarming rate of 0.25-0.5 °C/hour, and the effect of temperature control with fever prevention found no differences in outcomes.
CONCLUSIONS: This updated systematic review showed no benefit of temperature control at 32-34 °C compared to normothermia or 36 °C, although the 95% confidence intervals cannot rule out a potential beneficial effect. Important knowledge gaps exist for topics such as hypothermic temperature targets, rewarming rate, and fever control.
参考来源
- Granfeldt A, Holmberg MJ, Nolan JP, et al. Temperature control after adult cardiac arrest: An updated systematic review and meta-analysis. Resuscitation. 2023. PMID: 37558083. doi:10.1016/j.resuscitation.2023.109928
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。